Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Woodcock to the Rescue: Is CDER Approving More Products?

This article was originally published in RPM Report

Executive Summary

The financial community believes in Janet Woodcock: some analysts are predicting an improving climate for drug approvals based on her return to FDA's Center for Drug Evaluation & Research. Woodcock says standards aren't changing-but she does seem to relish making the tough decisions that make some approvals possible.

You may also be interested in...



FDAAA Pays Off: Drug Safety Controls Bring Immediate Returns to Sponsors

Companies as diverse as CV Therapeutics, UCB, GSK, Pozen and Biovail are all smiles about becoming unwitting guinea pigs in the new era of drug safety. None could have expected to be pioneers in facing new post-marketing burdens-but all are thrilled that their products were approved at all. And most have seen an immediate payback for their investors.

Turnaround at FDA's Drug Center: An Interview with Janet Woodcock

Janet Woodcock returned to the Center for Drug Evaluation & Research after four years as FDA commissioner Andrew von Eschenbach's right-hand woman. We talked to her about why she went back, how things have changed and the challenges that lie ahead.

The REMS Era Begins: FDA Applies Soft Touch With New Drug Safety Tools

Congress gave FDA some tough new tools to regulate drugs in September, but no one could know for sure how FDA would use them. Now there is some actual real world experience to judge by: a half-dozen drugs approved by FDA are subject to either a Risk Evaluation & Mitiagation Strategy or a mandatory post-marketing commitment. So far, the news is good for drug developers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel